Literature DB >> 7353209

Effects of hyperthermia in a malignant tumor.

L F Fajardo, B Egbert, J Marmor, G M Hahn.   

Abstract

The mechanisms of immediate and delayed tumor cell killing by hyperthermia were investigated in EMT-6 neoplasms implanted in BALB/cKa mice. Radiofrequency electromagnetic fields were used to achieve a curative local dose of 44 degrees C for 30 minutes. The tumors were sampled sequentially, during and after heat therapy, and studied by light and elecron microscopy. Assays for cell survival, including cell cultures, were performed at various times after completion of therapy. Focal cytoplasmic swelling, rupture of the plasma membrane and peripheral migration of heterochromatin were observed 5 minutes after initiation of therapy and led to cytoplasmic fragmentation by the end of the treatment period (30 minutes). Necrosis of most cells occurred 2--6 hours after the end of treatment. At 48 hours, there were no recognizable tumor cells. A scar replaced the tumor bed 14 days later. Viable (clonogenic) tumor cells were still 2% of control levels at the end of therapy and then progressively decreased to 0.0003% at 48 hours, confirming the morphologic observations and indicating that factors other than the direct effect of heat on tumor cells contributed to complete tumor eradication. Our findings, coupled with previous studies, suggest that the immediate heat induced necrosis in this tumor occurs through the mechanisms of physical changes in the plasma membrane. The delayed (post-therapy) cell death is likely due to modifications in the environment of the tumor bed.

Entities:  

Mesh:

Year:  1980        PMID: 7353209     DOI: 10.1002/1097-0142(19800201)45:3<613::aid-cncr2820450331>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

Review 1.  Thermal ablation of tumours: biological mechanisms and advances in therapy.

Authors:  Katrina F Chu; Damian E Dupuy
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

2.  The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy.

Authors:  Andrew R Burke; Ravi N Singh; David L Carroll; James C S Wood; Ralph B D'Agostino; Pulickel M Ajayan; Frank M Torti; Suzy V Torti
Journal:  Biomaterials       Date:  2012-01-14       Impact factor: 12.479

3.  Infrared hyperthermia and psoriasis.

Authors:  W Westerhof; A H Siddiqui; R H Cormane; A Scholten
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

Review 4.  Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: lessons learned from PRODIGE 7.

Authors:  Peter Cashin; Paul H Sugarbaker
Journal:  J Gastrointest Oncol       Date:  2021-04

5.  Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg.

Authors:  J D Nagel; I Krüger; F Ghussen; U Bode
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  A prospective randomized study of regional extremity perfusion in patients with malignant melanoma.

Authors:  F Ghussen; K Nagel; W Groth; J M Müller; H Stützer
Journal:  Ann Surg       Date:  1984-12       Impact factor: 12.969

Review 7.  Hyperthermia treatment advances for brain tumors.

Authors:  Georgios P Skandalakis; Daniel R Rivera; Caroline D Rizea; Alexandros Bouras; Joe Gerald Jesu Raj; Dominique Bozec; Constantinos G Hadjipanayis
Journal:  Int J Hyperthermia       Date:  2020-07       Impact factor: 3.914

Review 8.  Carbon nanotubes in hyperthermia therapy.

Authors:  Ravi Singh; Suzy V Torti
Journal:  Adv Drug Deliv Rev       Date:  2013-08-08       Impact factor: 15.470

9.  Stromal sensitivity to radiation and hyperthermia.

Authors:  S A Hill; K A Smith; J Denekamp
Journal:  Br J Cancer       Date:  1987-10       Impact factor: 7.640

10.  Comparison between interstitial laser thermotherapy and excision of an adenocarcinoma transplanted into rat liver.

Authors:  P H Möller; K Ivarsson; U Stenram; M Radnell; K G Tranberg
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.